Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Single Arm Phase II Study on Pembrolizumab and Chemotherapy as Perioperative Treatment Followed by Nasopharyngectomy and Maintenance Pembrolizumab for Locally Recurrent Nasopharyngeal Carcinoma (PINNACLE)

NCT07129772 is registered in ClinicalTrials.gov with The University of Hong Kong as lead sponsor.

NCT NCT07129772
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07129772 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Single Arm Phase II Study on Pembrolizumab and Chemotherapy as Perioperative Treatment Followed by Nasopharyngectomy and Maintenance Pembrolizumab for Locally Recurrent Nasopharyngeal Carcinoma (PINNACLE)
Lead sponsor
The University of Hong Kong
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 1, 2025
Completion date
June 30, 2028
Enrollment
53 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nasopharyngeal cancer recurrent, nasopharyngeal cancinoma (npc)